



Corporate Profile



Overview

A private biotechnology company based in Vancouver, Canada, Sirius Genomics correlates patient genetics with clinical information to develop DNA-based companion diagnostic tests for acute medical conditions. These companion diagnostics (CDx) improve therapeutic decisions, leading to better drug use and patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The company's lead CDx product is a genetic predictor of response to treatment for sepsis, a deadly systemic blood infection that impacts 750,000 people annually.

“Our Vision: Rx through Dx-
We believe that ultimately all prescriptions
will be accessed through a diagnostic”
— Chris Wagner, President and CEO

Market Opportunity

Personalized Medicine

Pharmaceutical companies are turning to pharmacogenomics to understand how drugs may act differently and with varying efficacy given patient genotype. The new drug area, called “Personalized Medicine”, aims to help physicians prescribe the right treatment for the right patient at the right time.

Companion Diagnostics

A subset of personalized medicine, pharmacogenetic companion diagnostic testing identifies a specific genetic variation that may lead to improved or worsened patient outcomes given the administration of a particular drug. Prior to prescribing a drug, physicians use such a diagnostic test to reveal whether or not a patient has a genotype with a propensity to benefit or not from its action in the body. Companion diagnostics can provide doctors with information they need to more accurately prescribe medicines, reducing risk and costs to the medical system as a whole.


Technology


Sirius Genomics' expertise lies in our ability to correlate genes with physical attributes and apply our clinical and regulatory knowledge to translate these biomarker discoveries into potential companion diagnostics.

Specifically, we look for Single Nucleotide Polymorphisms (SNPs) within genes of interest to determine patient response to a drug compound. In studying the correlation between phenotype and genotype we look for SNPs that function as biomarkers that predict a positive or adverse response to a drug. These genetic correlations to clinical outcomes form the proprietary foundation for the companion diagnostic tests that Sirius Genomics develops.

In the search for SNPs predictive of improved outcome for recombinant human-activated protein C-treated patients, the Sirius team has built a powerful methodology. The rigorous three-phase research and development strategy—discovery, replication and validation—mirrors the process for drug development.

DNA molecule 1 differs from
DNA molecule 2 at the same location





Corporate Profile

Products

Our lead product is a companion diagnostic for recombinant human-activated protein C the only approved drug to treat severe sepsis. Sepsis is the second leading cause of mortality in hospitals with over 200,000 deaths annually.

Sirius is developing a bedside diagnostic kit with the goal of identifying sepsis patients with a genotype associated with improved survival after treatment with activated protein C. The purpose of this companion diagnostic kit is to aid physicians in their decision making process when prescribing activated protein C, with the ultimate aim to increase patient survival rates.


Business Model

Sirius Genomics partners with pharmaceutical companies that can apply its platform and capabilities to:

- » Previously failed or underperforming drugs
- » Drugs in clinical trials
- » New indications for currently approved drugs

By generating a companion diagnostic for a pharmaceutical in any of these categories, Sirius can help to improve prescription accuracy, patient outcomes and drug uptake curves, unlocking the promise of personalized medicine.

Pipeline:



Activated Protein C CDx: A molecular diagnostic test to identify patients who will respond to activated protein C, the only FDA approved drug for sepsis.

Management Team

Founded in 2001 by acute care physicians Drs. James Russell and Keith Walley, Sirius Genomics has expanded, bringing together a management team and board with deep expertise in genetic associations, clinical trials, regulatory processes, intellectual property management, and commercialization in pharmaceuticals, devices and diagnostics

For more information on Sirius Genomics, our team, research and development strategy, product pipeline, investors and partners visit: www.siriusgenomics.com

"Sepsis patients have very high mortality rates. When activated protein C came out, it was the first new sepsis drug available in 20 years. If we could make it more successful, our hope is that fewer patients would die."

- Jim Russell, Co-founder, Medical Advisor

Contact us

For partner and/or investor inquiries contact:

Chris Wagner,
President & Chief Executive Officer
Tel: 604.484.7195
cwagner@siriusgenomics.com



Sirius Genomics Inc.
1125 Howe Street, Suite 603
Vancouver, BC V6Z 2K8 Canada
www.siriusgenomics.com

Telephone:
604 484 7195
Fax:
604 484 7190